SEMA3B and inflammatory bowel disease: Moreover, we investigated the therapeutic efficacy of Sema3B <i>in vivo</i>.<h4>Results</h4>Our findings revealed that the expression of <i>SEMA3B</i> was downregulated in IBD patients compared with healthy controls.